Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meriva in Rheumatoid Arthritis
NCT02543931Phase 1Terminated
- Sponsor
- University of Arizona
- Start
- Nov 2015
- Primary completion
- Jun 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of phosphatidylcholine-curcumin complex in rheumatoid arthritis (RA) (3 arms), sponsored by University of Arizona. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 4 weeks, Area under curve and 3 more. Started Nov 2015; status: terminated.
02
Drugs
phosphatidylcholine-curcumin complex
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02543931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543931.